These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 27260014)

  • 1. Unraveling the Pivotal Role of Bradykinin in ACE Inhibitor Activity.
    Taddei S; Bortolotto L
    Am J Cardiovasc Drugs; 2016 Oct; 16(5):309-21. PubMed ID: 27260014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacology of ACE inhibitors versus AT1 blockers.
    Vaughan D
    Can J Cardiol; 2000 Aug; 16 Suppl E():36E-40E. PubMed ID: 10906625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms involved in the angiotensin II-independent hypotensive action of ACE inhibitors.
    Hecker M; Pörsti I; Busse R
    Braz J Med Biol Res; 1994 Aug; 27(8):1917-21. PubMed ID: 7749381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterogeneity of endothelium-dependent vasodilator effects of angiotensin-converting enzyme inhibitors: role of bradykinin generation during ACE inhibition.
    Mombouli JV; Vanhoutte PM
    J Cardiovasc Pharmacol; 1992; 20 Suppl 9():S74-82. PubMed ID: 1282634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular protective effects of angiotensin converting enzyme inhibitors and their relation to clinical events.
    Enseleit F; Hürlimann D; Lüscher TF
    J Cardiovasc Pharmacol; 2001 Apr; 37 Suppl 1():S21-30. PubMed ID: 11392475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of reduced angiotensin-converting enzyme gene expression and angiotensin-converting enzyme inhibition on angiotensin and bradykinin peptide levels in mice.
    Campbell DJ; Alexiou T; Xiao HD; Fuchs S; McKinley MJ; Corvol P; Bernstein KE
    Hypertension; 2004 Apr; 43(4):854-9. PubMed ID: 14769811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endothelium-dependent effects of converting-enzyme inhibitors.
    Vanhoutte PM; Boulanger CM; Illiano SC; Nagao T; Vidal M; Mombouli JV
    J Cardiovasc Pharmacol; 1993; 22 Suppl 5():S10-6. PubMed ID: 7508046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of bradykinin in the cardiac effects of angiotensin-converting enzyme inhibitors.
    Linz W; Schölkens BA
    J Cardiovasc Pharmacol; 1992; 20 Suppl 9():S83-90. PubMed ID: 1282635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of converting enzyme inhibition on endothelial bradykinin metabolism and endothelium-dependent vascular relaxation.
    Bossaller C; Auch-Schwelk W; Gräfe M; Graf K; Baumgarten C; Fleck E
    Agents Actions Suppl; 1992; 38 ( Pt 3)():171-7. PubMed ID: 1334349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Local action of the renin angiotensin system in the porcine ophthalmic circulation: effects of ACE-inhibitors and angiotensin receptor antagonists.
    Meyer P; Flammer J; Lüscher TF
    Invest Ophthalmol Vis Sci; 1995 Mar; 36(3):555-62. PubMed ID: 7890486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Endothelial mechanisms in vasomotor effects of ACE inhibitors].
    Busse R; Hecker M
    Z Kardiol; 1994; 83 Suppl 4():1-6. PubMed ID: 7856274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bradykinin, angiotensin-(1-7), and ACE inhibitors: how do they interact?
    Tom B; Dendorfer A; Danser AH
    Int J Biochem Cell Biol; 2003 Jun; 35(6):792-801. PubMed ID: 12676166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potentiation of bradykinin effect by angiotensin-converting enzyme inhibition does not correlate with angiotensin-converting enzyme activity in the rat mesenteric arteries.
    Sivieri DO; Bispo-da-Silva LB; Oliveira EB; Resende AC; Salgado MC
    Hypertension; 2007 Jul; 50(1):110-5. PubMed ID: 17470724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endothelial function and bradykinin in humans.
    Hornig B; Drexler H
    Drugs; 1997; 54 Suppl 5():42-7. PubMed ID: 9429844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Bradykinin and cardiovascular protection. Role of perindopril, an inhibitor of angiotensin conversion enzyme].
    Lancellotti P; Ancion A; D'Orio V; Gach O; Maréchal P; Krzesinski JM
    Rev Med Liege; 2018 Apr; 73(4):197-205. PubMed ID: 29676873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathophysiologic and therapeutic importance of tissue ACE: a consensus report.
    Dzau VJ; Bernstein K; Celermajer D; Cohen J; Dahlöf B; Deanfield J; Diez J; Drexler H; Ferrari R; Van Gilst W; Hansson L; Hornig B; Husain A; Johnston C; Lazar H; Lonn E; Lüscher T; Mancini J; Mimran A; Pepine C; Rabelink T; Remme W; Ruilope L; Ruzicka M; Schunkert H; Swedberg K; Unger T; Vaughan D; Weber M
    Cardiovasc Drugs Ther; 2002 Mar; 16(2):149-60. PubMed ID: 12090908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective angiotensin-converting enzyme C-domain inhibition is sufficient to prevent angiotensin I-induced vasoconstriction.
    van Esch JH; Tom B; Dive V; Batenburg WW; Georgiadis D; Yiotakis A; van Gool JM; de Bruijn RJ; de Vries R; Danser AH
    Hypertension; 2005 Jan; 45(1):120-5. PubMed ID: 15583077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of neutral endopeptidase inhibition and combined angiotensin converting enzyme and neutral endopeptidase inhibition on angiotensin and bradykinin peptides in rats.
    Campbell DJ; Anastasopoulos F; Duncan AM; James GM; Kladis A; Briscoe TA
    J Pharmacol Exp Ther; 1998 Nov; 287(2):567-77. PubMed ID: 9808682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kinin-related effects of angiotensin-converting enzyme inhibition.
    Bönner G
    Clin Physiol Biochem; 1990; 8 Suppl 1():6-15. PubMed ID: 2257722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-ischemic potential of drugs related to the renin-angiotensin system.
    Ertl G; Hu K
    J Cardiovasc Pharmacol; 2001 Apr; 37 Suppl 1():S11-20. PubMed ID: 11392474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.